Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
February 5, 2019
Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock
AUSTIN, Texas, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for ...
February 4, 2019
CytoSorbents Announces the Data Safety Monitoring Board Recommends Continuation of REMOVE Endocarditis Trial
MONMOUTH JUNCTION, N.J., Feb. 4, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill ...
February 4, 2019
Oncolytics Biotech to Present at the 21st Annual BIO CEO & Investor Conference
CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / February 4, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic ...
February 4, 2019
BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer
TEL AVIV, Israel, Feb. 4, 2019 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that the U.S. Food and ...
February 4, 2019
Athenex Announces Late-Breaking Oral Presentation of KX2-391 Ointment in Two Phase III Studies at the American Academy of Dermatology Annual Meeting
BUFFALO, N.Y., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for ...
February 4, 2019
Check-Cap Ltd. Announces $7.5 Million Registered Direct Offering
ISFIYA, Israel, Feb. 4, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (CHEKZ), a clinical-stage medical diagnostics company offering C-Scan®, the first and ...
February 4, 2019
Allakos to Host Investor Day on February 19 in New York City
REDWOOD CITY, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell ...
February 4, 2019
Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans
PALO ALTO, Calif., Feb. 4, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced ...
February 4, 2019
AIT Receives $3.15 Million Milestone Payment from Commercialization Partner Circassia Pharmaceuticals
GARDEN CITY, N.Y. and REHOVOT, Israel, Feb. 04, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on ...
February 4, 2019
BioDelivery Announces Expanded Preferred Insurance Coverage For BELBUCA®
RALEIGH, N.C., Feb. 04, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with ...
February 4, 2019
Aimmune Therapeutics to Present AR101, OIT and Peanut Allergy Data at 2019 AAAAI Annual Meeting
BRISBANE, Calif.--(BUSINESS WIRE)-- — Nine Abstracts Featured, Including Data on Longer-Term AR101 Efficacy and Safety and PALISADE Accidental Exposures — Aimmune Therapeutics, Inc. (AIMT), a ...
February 4, 2019
INVENTIVA : New results on lanifibranor to be presented at the International Liver Congress 2019
Daix (France), February 4, 2019 - Inventiva S.A. ("Inventiva"), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis ("NASH"), systemic sclerosis and mucopolysaccharidosis ("MPS"), today ...
February 4, 2019
Prothena to Report Fourth Quarter and Full Year 2018 Financial Results and Host Webcast Conference Call on February 14
DUBLIN, Ireland, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (PRTA), a clinical-stage neuroscience company, announced today that it will report its fourth quarter ...
February 1, 2019
What is a Non Deal Roadshow? Strong relationships with investors usually lead to more profitable investments. The big question is, how can these relationships be ...
January 31, 2019
VALNEVA Reports Positive Initial Booster Data and Final Phase 1 Data for its Lyme Disease Vaccine Candidate
Saint-Herblain (France), January 31, 2019 - Valneva SE ("Valneva"), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, today announced ...
January 31, 2019
Fortress Biotech Announces CAEL-101 Strategic Partnership with Alexion Pharmaceuticals
NEW YORK, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and ...
January 31, 2019
Entera Bio Announces Positive Feedback and Guidance from the US FDA Regarding its Development Plans for Oral PTH in Osteoporosis
JERUSALEM, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (ENTX), announced today the positive outcome of a pre-IND meeting held with the US Food ...
January 31, 2019
Catalyst Biosciences Announces Oral and Poster Presentations at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...
January 31, 2019
Zosano Announces Publication of Positive Data on Qtrypta’s™ Potential as an Acute Treatment for Patients with Difficult-to-Treat Migraines
FREMONT, Calif., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the peer-reviewed publication ...
January 31, 2019
Genkyotex Provides Corporate Update and Reports Cash Position at December 31, 2018
Genkyotex (Euronext Paris & Brussels: FR0011790542 – GKTX) (GKTX.PA) (GKTX.PA), a biopharmaceutical company and the leader in NOX therapies, today provided a corporate update, and ...
Page 28 of 150